Buscar
Mostrando ítems 1-6 de 6
Possible implications of dysregulated nicotinic acetylcholine receptor diffusion and nanocluster formation in myasthenia gravis
(Shenyang Editorial Dept Neural Regeneration Res, 2021-02)
Myasthenia gravis is a rare and invalidating disease affecting the neuromuscular junction of voluntary muscles. The classical form of this autoimmune disease is characterized by the presence of antibodies against the most ...
C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
(SAGE Publications, 2020-08)
Background: Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration ...
Autoimmune Attack of the Neuromuscular Junction in Myasthenia Gravis: Nicotinic Acetylcholine Receptors and Other Targets
(American Chemical Society, 2019-04)
The nicotinic acetylcholine receptor (nAChR) family, the archetype member of the pentameric ligand-gated ion channels, is ubiquitously distributed in the central and peripheral nervous systems and its members are the targets ...
Antibody-induced crosslinking and cholesterol-sensitive, anomalous diffusion of nicotinic acetylcholine receptors
(Wiley Blackwell Publishing, Inc, 2020-03)
Synaptic strength depends on the number of cell-surface neurotransmitter receptors in dynamic equilibrium with intracellular pools. Dysregulation of this homeostatic balance occurs, for example in myasthenia gravis, an ...
El pico flujo espiratorio y la cuenta máxima son marcadores del compromiso respiratorio en la miastenia gravisPeak expiratory flow and the single-breath counting test as markers of respiratory function in patients with myasthenia gravis
(Elsevier, 2020-12)
Introducción: La miastenia gravis (MG) es una enfermedad autoinmune mediada por anticuerpos. El cuadro clínico se caracteriza por debilidad muscular fluctuante y fatigable, con frecuente afectación de músculos fonodeglutorios ...
A comparative in vitro assay of drug release performance of pyridostigmine bromide tablets
(Dissolution Technologies, Inc, 2007-11)
Myasthenia gravis is an autoimmune disease that destroys key components of the neuromuscular system. The most common therapy uses reversible inhibitors of cholinesterase activity, such as pyridostigmine bromide (PB). The ...